Journal ArticleOPEN ACCESS

MAGE-A3-specific anticancer immunotherapy in the clinical practice

OncoImmunology (2013) 2(10)
DOI: 10.4161/onci.25995
13Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS 15, a multicomponent immunostimulant, was found to elicit robust antigen-specific immune responses. © 2013 Landes Bioscience.

Author supplied keywords

Cite

CITATION STYLE

APA

Brichard, V. G., & Godechal, Q. (2013). MAGE-A3-specific anticancer immunotherapy in the clinical practice. OncoImmunology, 2(10). https://doi.org/10.4161/onci.25995

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free